Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | EPAS1 | Q99814 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 5/20 | 0.39 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17033109 | 0.85 | USP28 (0.42) | LMNANR1H2NR1H3ALDH1A1CTSS | |
| SCHEMBL17033097 | 0.84 | POLB (0.45) | LMNAHTTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL17031833 | 0.82 | MEN1 (0.43) | LMNAHTTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL19353236 | 0.81 | MEN1 (0.41) | LMNAHTTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL17039359 | 0.78 | MEN1 (0.43) | LMNAHTTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL17033102 | 0.75 | FFAR4 (0.40) | CTSSCTSK | |
| SCHEMBL10233503 | 0.72 | MEN1 (0.54) | LMNAHTTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL17033285 | 0.72 | HSD17B10 (0.36) | HTTKMT2AALDH1A1 | |
| SCHEMBL19333932 | 0.72 | ALB (0.31) | — | |
| SCHEMBL17039404 | 0.72 | EIF4E (0.39) | SMN1; SMN2MEN1KMT2AALDH1A1CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150239895-A1 | Aryl, Heteroaryl, and Heterocyclic Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239895-A1 | Aryl, Heteroaryl, and Heterocyclic Compounds for Treatment of Complement Mediated Disorders | TFPI, CFD, F3 | LMNA 1587/4885HTT 1073/4885SMN1; SMN2 1770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.